litlas
Log inCreate account

Michael A. Morse

Active 1995–2025

Also published as
Michael A Morse
129
Papers
25,504
Citations
84
h-index
124
i10-index

Citations

Citations per year for Michael A. Morse1996: 1 citations1997: 2 citations1998: 2 citations1999: 8 citations2000: 24 citations2001: 39 citations2002: 35 citations2003: 59 citations2004: 59 citations2005: 52 citations2006: 71 citations2007: 66 citations2008: 92 citations2009: 156 citations2010: 140 citations2011: 147 citations2012: 141 citations2013: 131 citations2014: 151 citations2015: 152 citations2016: 173 citations2017: 256 citations2018: 351 citations2019: 987 citations2020: 1,339 citations2021: 1,299 citations2022: 982 citations2023: 786 citations2024: 1,134 citations2025: 552 citations2026: 11 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,246 citing papers, 25.4% of this breakdownChina: 1,886 citing papers, 14.8% of this breakdownItaly: 749 citing papers, 5.9% of this breakdownGermany: 655 citing papers, 5.1% of this breakdownUnited Kingdom: 601 citing papers, 4.7% of this breakdownFrance: 589 citing papers, 4.6% of this breakdownSpain: 441 citing papers, 3.5% of this breakdownJapan: 406 citing papers, 3.2% of this breakdownCanada: 325 citing papers, 2.5% of this breakdownNetherlands: 325 citing papers, 2.5% of this breakdownAustralia: 287 citing papers, 2.3% of this breakdownSouth Korea: 259 citing papers, 2% of this breakdown
0%25.4%Other 23.5%

Institutions

Fields

  • Medicine62.6%
  • Biochemistry, Genetics and Molecular Biology21.8%
  • Immunology and Microbiology11.8%
  • Engineering1.8%
  • Neuroscience0.4%
  • Materials Science0.4%
  • Other1.2%

Topics

  • Cancer Immunotherapy and Biomarkers10.5%
  • Immunotherapy and Immune Responses6%
  • Colorectal Cancer Treatments and Studies3.7%
  • Extracellular vesicles in disease3.3%
  • CAR-T cell therapy research3.1%
  • Genetic factors in colorectal cancer2.6%
  • Other70.8%

Coauthors

All papers

Open in search
  1. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

    Authors: Michael J. Overman, Ray McDermott, Joseph L. Leach, Sara Lonardi, Heinz‐Josef Lenz, Michael A. Morse, Jayesh Desai, Andrew Hill, Michael D. Axelson, Rebecca A. Moss, Monica V. Goldberg, Z. Alexander Cao, Jean-Marie Ledeine, Gregory A. Maglinte, Scott Kopetz, Thierry André - The Lancet Oncology 2017 cited by 2,816

  2. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

    Authors: Michael J. Overman, Sara Lonardi, Ka Yeung Mark Wong, Heinz‐Josef Lenz, Fabio Gelsomino, Massimo Aglietta, Michael A. Morse, Eric Van Cutsem, Ray McDermott, Andrew Hill, Michael B. Sawyer, Alain Hendlisz, Bart Neyns, Magali Svrcek, Rebecca A. Moss, Jean-Marie Ledeine, Z. Alexander Cao, Shital Kamble, Scott Kopetz, Thierry André - Journal of Clinical Oncology 2018 cited by 2,070

  3. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer

    Authors: Michael A. Morse, Jennifer Garst, Takuya Osada, Shubi Khan, Amy Hobeika, Timothy M. Clay, Nancy Valente, Revati Shreeniwas, Mary Ann Sutton, Alain Delcayre, Di‐Hwei Hsu, Jean‐Bernard Le Pecq, H. Kim Lyerly - Journal of Translational Medicine 2005 cited by 1,115

  4. Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians

    Authors: Dimitrios Moris, Manisha Palta, Charles Kim, Peter J. Allen, Michael A. Morse, Michael E. Lidsky - CA A Cancer Journal for Clinicians 2022 cited by 468

  5. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

    Authors: Scott Antonia, José A. López-Martín, Johanna C. Bendell, Patrick A. Ott, Matthew H. Taylor, Joseph P. Eder, Dirk Jäger, M. Catherine Pietanza, Dung T. Le, Filippo de Braud, Michael A. Morse, Paolo A. Ascierto, Leora Horn, Asim Amin, Rathi N. Pillai, Jeffry Evans, Ian Chau, Petri Bono, Akin Atmaca, Padmanee Sharma, Christopher Harbison, Chen-Sheng Lin, Olaf Christensen, Emiliano Calvo - The Lancet Oncology 2016 cited by 1,254

  6. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142

    Authors: Thierry André, Sara Lonardi, Ka Yeung Mark Wong, H.J. Lenz, Fabio Gelsomino, Massimo Aglietta, Michael A. Morse, Eric Van Cutsem, Ray McDermott, Andrew Hill, Michael B. Sawyer, Alain Hendlisz, Bart Neyns, Sandzhar Abdullaev, Arteid Memaj, Ming Lei, Michael F. Dixon, Scott Kopetz, Michael J. Overman - Annals of Oncology 2022 cited by 253

  7. The Role of Angiogenesis in Hepatocellular Carcinoma

    Authors: Michael A. Morse, Weijing Sun, Richard D. Kim, Aiwu Ruth He, Paolo Abada, Michelle Mynderse, Richard S. Finn - Clinical Cancer Research 2018 cited by 546

  8. Vaccine Therapies for Cancer: Then and Now

    Authors: Michael A. Morse, William R. Gwin, Duane A. Mitchell - Targeted Oncology 2021 cited by 214

  9. Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes–Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer

    Authors: Dung T. Le, Andrea Wang‐Gillam, Vincent J. Picozzi, Tim F. Greten, Todd S. Crocenzi, Gregory M. Springett, Michael A. Morse, Herbert J. Zeh, Deirdre Jill Cohen, Robert L. Fine, Beth Onners, Jennifer N. Uram, Daniel A. Laheru, Eric R. Lutz, Sara Solt, Aimee Murphy, Justin Skoble, Ed Lemmens, John Grous, Thomas W. Dubensky, Dirk G. Brockstedt, Elizabeth M. Jaffee - Journal of Clinical Oncology 2015 cited by 600

  10. Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose

    Authors: Christine H. Chung, Beloo Mirakhur, Emily Chan, Quynh‐Thu Le, Jordan Berlin, Michael A. Morse, Barbara A. Murphy, Shama M. Satinover, Jacob D. Hosen, David Mauro, Robbert J.C. Slebos, Qinwei Zhou, Diane R. Gold, Tina Hatley, Daniel J. Hicklin, Thomas A.E. Platts‐Mills - New England Journal of Medicine 2008 cited by 1,483

  11. Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)

    Authors: Dung T. Le, Vincent J. Picozzi, Andrew H. Ko, Zev A. Wainberg, Hedy L. Kindler, Andrea Wang‐Gillam, Paul E. Oberstein, Michael A. Morse, Herbert J. Zeh, Colin D. Weekes, Tony Reid, Erkut Borazanci, Todd S. Crocenzi, Noelle K. LoConte, Benjamin Musher, Dan Laheru, Aimee Murphy, Chan C. Whiting, Nitya Nair, Amanda Enstrom, Sandy Ferber, Dirk G. Brockstedt, Elizabeth M. Jaffee - Clinical Cancer Research 2019 cited by 261

  12. Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results

    Authors: Padmanee Sharma, Arlene O. Siefker‐Radtke, Filippo de Braud, Umberto Basso, Emiliano Calvo, Petri Bono, Michael A. Morse, Paolo A. Ascierto, José A. López-Martín, Peter Brossart, Kristoffer Staal Rohrberg, Begoña Mellado, Bruce S. Fischer, S. Meadows–Shropshire, Abdel Saci, Margaret K. Callahan, Jonathan E. Rosenberg - Journal of Clinical Oncology 2019 cited by 243

  13. Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)

    Authors: Li-Chung Tsao, John S. Wang, Xingru Ma, Sirajbir Sodhi, Joey V. Ragusa, Bushangqing Liu, Jason McBane, Tao Wang, Jun-Ping Wei, Cong-Xiao Liu, Xiao Yang, Gangjun Lei, Ivan Spasojević, Ping Fan, Timothy N. Trotter, Michael A. Morse, H. Kim Lyerly, Zachary C. Hartman - Nature Communications 2025 cited by 104

  14. Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets

    Authors: Benjamin A. Weinberg, Joanne Xiu, Michael Lindberg, Anthony F. Shields, Jimmy J. Hwang, Kelsey Poorman, Mohamed E. Salem, Michael J. Pishvaian, Randall F. Holcombe, John Marshall, Michael A. Morse - Journal of Gastrointestinal Oncology 2019 cited by 183

  15. 1-Year Outcomes With Fourth-Generation Mitral Valve Transcatheter Edge-to-Edge Repair From the EXPAND G4 Study

    Authors: Ralph Stephan von Bardeleben, Paul Mahoney, Michael A. Morse, Matthew J. Price, Paolo Denti, Francesco Maisano, Jason H. Rogers, Michael Rinaldi, Federico De Marco, William Rollefson, Bassem Chehab, Mathew Williams, Guillaume Leurent, Federico M. Asch, Evelio Rodríguez - JACC: Cardiovascular Interventions 2023 cited by 124

  16. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity

    Authors: Shinya Abe, Hiroshi Nagata, Erika J Crosby, Yoshiyuki Inoue, Kensuke Kaneko, Cong-Xiao Liu, Xiao Yang, Tao Wang, Chaitanya R Acharya, Pankaj Agarwal, Joshua Snyder, William Gwin, Michael A Morse, Pei Zhong, Herbert Kim Lyerly, Takuya Osada - Journal for ImmunoTherapy of Cancer 2022 cited by 74

  17. Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium

    Authors: Talal El Zarif, Amin H. Nassar, Elio Adib, Bailey G. Fitzgerald, Jiaming Huang, Tarek H. Mouhieddine, P Rubinstein, Taylor K. Nonato, Rana R. McKay, Mingjia Li, Arjun Mittra, Dwight H. Owen, Robert A. Baiocchi, Michael Lorentsen, Christopher Dittus, Nazlı Dizman, Adewunmi Falohun, Noha Abdel‐Wahab, Adi Diab, Anand Bankapur, Alexandra Reed, Chul Kim, Aakriti Arora, Neil J. Shah, Edward El‐Am, Elie Kozaily, Wassim Abdallah, Ahmad Al‐Hader, Batool Abu Ghazal, Anwaar Saeed, Claire Drolen, Melissa G. Lechner, Alexandra Drakaki, Javier Baena, Caroline A. Nebhan, Tarek Haykal, Michael A. Morse, Alessio Cortellini, David J. Pinato, Alessia Dalla Pria, Evan Hall, Veli Bakalov, Nathan Bahary, Aarthi Rajkumar, Ankit Mangla, Vishal Shah, Parminder Singh, Frank Aboubakar Nana, Nerea Lopetegui‐Lia, Danai Dima, Ryan W. Dobbs, Pauline Funchain, Rabia Saleem, Rachel Woodford, Georgina V. Long, Alexander M. Menzies, Carlo Genova, Giulia Barletta, Sonam Puri, Vaia Florou, Damé Idossa, Maristella Saponara, Paola Queirolo, Giuseppe Lamberti, Alfredo Addeo, Melissa Bersanelli, Dory Freeman, Wanling Xie, Erin Reid, Elizabeth Y. Chiao, Elad Sharon, Douglas B. Johnson, Ramya Ramaswami, Mark Bower, Brinda Emu, Thomas U. Marron, Toni K. Choueiri, Lindsey R. Baden, Kathryn Lurain, Guru Sonpavde, Abdul Rafeh Naqash - Journal of Clinical Oncology 2023 cited by 69

  18. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

    Authors: Padmanee Sharma, Margaret K. Callahan, Petri Bono, Joseph W. Kim, Pavlina Spiliopoulou, Emiliano Calvo, Rathi N. Pillai, Patrick A. Ott, Filippo de Braud, Michael A. Morse, Dung T. Le, Dirk Jaeger, Emily Chan, Chris Harbison, Chen-Sheng Lin, Marina Tschaika, Alex Azrilevich, Jonathan E. Rosenberg - The Lancet Oncology 2016 cited by 685

  19. Randomized Comparison of Transcatheter Edge-to-Edge Repair for Degenerative Mitral Regurgitation in Prohibitive Surgical Risk Patients

    Authors: D. Scott Lim, Robert L. Smith, Linda D. Gillam, Firas Zahr, Scott Chadderdon, Raj Makkar, Ralph Stephan von Bardeleben, Robert Kipperman, Andrew N. Rassi, Molly Szerlip, Scott Goldman, Ignacio Inglessis‐Azuaje, Pradeep Yadav, Philipp Lurz, Charles J. Davidson, Mubashir Mumtaz, Hemal Gada, Saibal Kar, Susheel Kodali, Roger J. Laham, William Hiesinger, Neil Fam, Mirjam Keßler, William W. O’Neill, Brian Whisenant, Chad Kliger, Samir Kapadia, Volker Rudolph, Joseph Choo, James Hermiller, Michael A. Morse, Niklas Schofer, Sameer Gafoor, Azeem Latib, Konstantinos Koulogiannis, Leo Marcoff, Jörg Hausleiter - JACC: Cardiovascular Interventions 2022 cited by 147

  20. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients

    Authors: Takuya Osada, Gabriel T. Chong, Robert L. Tansik, Timothy Hong, Neil L. Spector, Rakesh Kumar, Herbert I. Hurwitz, I K Dev, Andrew B. Nixon, H. Kim Lyerly, Timothy Clay, Michael A. Morse - Cancer Immunology Immunotherapy 2008 cited by 310

  21. Where We Stand With Immunotherapy in Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management

    Authors: Michael J. Overman, Marc S. Ernstoff, Michael A. Morse - American Society of Clinical Oncology Educational Book 2018 cited by 130

  22. Clinical trials of self-replicating RNA-based cancer vaccines

    Authors: Michael A. Morse, Erika J. Crosby, Jeremy Force, Takuya Osada, Amy Hobeika, Zachary C. Hartman, Peter Berglund, Jonathan Smith, H. Kim Lyerly - Cancer Gene Therapy 2023 cited by 54

  23. Antihelminth Compound Niclosamide Downregulates Wnt Signaling and Elicits Antitumor Responses in Tumors with Activating APC Mutations

    Authors: Takuya Osada, Minyong Chen, Xiao Yang, Ivan Spasojević, Jeffrey VanDeusen, David S. Hsu, Bryan M. Clary, Timothy M. Clay, Wei Chen, Michael A. Morse, H. Kim Lyerly - Cancer Research 2011 cited by 266

  24. One-Year Outcomes of Mitral Valve-in-Valve Using the SAPIEN 3 Transcatheter Heart Valve

    Authors: Brian Whisenant, Samir Kapadia, Mackram F. Eleid, Susheel Kodali, James M. McCabe, Amar Krishnaswamy, Michael A. Morse, Richard W. Smalling, Mark Reisman, Michael J. Mack, William W. O’Neill, Vinayak Bapat, Martin B. Leon, Charanjit S. Rihal, Raj Makkar, Mayra Guerrero - JAMA Cardiology 2020 cited by 178